

MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND V14 CHANGES TO VERSION 13

PUBLISHED APRIL 2019

Changes to v13



Lines removed

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/ AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)	COMMENT
ABATACEPT	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULT TA'S (TA195, TA373, TA375)	NICE	NICE	NICE			√		Now covered by comment 8
ADALIMUMAB	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	AS PER TA455 OR ADULT TA'S (TA130 (replaced by TA375), TA143 (replaced by TA383), TA146, TA187, TA199, TA329, TA392, TA460)	NICE	NICE	NICE AUDIT	√	√			Now covered by comment 8
ALBUTREPENONACOG ALFA	HAEMOPHILIA B	NHS ENGLAND	BLOOD-RELATED PRODUCTS	SSC 1652	SSC 1652	SSC 1652	PRODUCTS ON CMU FRAMEWORK		√			Blood factor products simplified to blood factor product VIII etc
ANAKINRA	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Now covered by comment 8
ANTIHAEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK			√		Blood factor products simplified to blood factor product VIII etc
APREMILAST	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Now covered by comment 8
ARAGAM	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
AVORALSTAT	HEREDITARY ANGIOEDEMA	NHS ENGLAND	ALLERGIC EMERGENCIES	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Never licensed
BARICITINIB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√		Now covered by comment 8
BERACTANT	RESPIRATORY DISTRESS SYNDROME	NHS ENGLAND	PULMONARY SURFACTANTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES				√		Moving into tariff
BRODALIMUMAB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√		Now covered by comment 8
CATRIDECACOG	CONGENITAL FACTOR XIII A-SUBUNIT DEFICIENCY	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Blood factor products simplified to blood factor product VIII etc
CERTOLIZUMAB PEGOL	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Now covered by comment 8
COBITOLIMOD	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√		Now covered by comment 8
DACLIZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Changed to NRC following loss of licence
DASABUVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 365	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	√	√			Corrected to reflect TA status

ETANERCEPT	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	AS PER TA455 OR ADULT TA'S (TA103, TA130, TA143, TA199)	NICE	NICE	NICE AUDIT	√		√		Now covered by comment 8
ETROLIZUMAB	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√		Now covered by comment 8
FILGRASTIM	BARTH SYNDROME	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY			√			Moving into tariff
FILGRASTIM	NEUTROPENIA	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	SPC	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY PRODUCT WITH LOWEST ACQUISITION COST TO BE USED			√		Moving into tariff but added to supportive drug list
FILGOTINIB	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√		Now covered by comment 8
FILIBUVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Never licensed
FLEBOGAMMA	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
FLEBOGAMMADIF	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
GAMMAGARD	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
GAMMANORM	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
GAMMAPLEX	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
GAMUNEX	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
GLYCOPEGYLATED FACTOR IX	HAEMOPHILIA A	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Blood factor products simplified to blood factor product VIII etc
GOLIMUMAB	PAEDIATRIC INDICATIONS	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULTS TA'S (TA220, TA233)	NICE	NICE	NICE AUDIT			√		Now covered by comment 8
HIZENTRA	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
HYQVIA	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Immunoglobulin products simplified to IV or sc
INFLIXIMAB	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULT TA'S (TA130 (replaced by TA375), TA134, TA140, TA143 (replaced by TA383), TA163, TA187, TA199, TA329)	NICE	NICE	NICE AUDIT	√		√		Now covered by comment 8
INTRATECT	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
KIOVIG	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
LENOGRASTIM	NEUTROPENIA	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	SPC	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY PRODUCT WITH LOWEST ACQUISITION COST TO BE USED			√		Moving into tariff
LENOGRASTIM	BARTH SYNDROME	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY			√			Moving into tariff but added to supportive drug list
LIPEFILGRASTIM	NEUTROPENIA	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Moving into tariff

MAVRILIMUMAB	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√		Now covered by comment 8
MOTAVIZUMAB	RSV PROPHYLAXIS	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Never licensed
NONACOG ALPHA (BeneFIX)	HAEMOPHILIA B	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES				√		Blood factor products simplified to blood factor product VIII etc
NONACOG BETA PEGOL	HAEMOPHILIA B	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Blood factor products simplified to blood factor product VIII etc
NORMAL IMMUNOGLOBULIN	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
OCTAGAM	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
PEGFILGRASTIM	NEUTROPENIA	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Moving into tariff
PEGINTERFERON LAMBDA-1A	HEPATITIS C	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Moving into tariff
PORACTANT ALFA	RESPIRATORY DISTRESS SYNDROME	NHS ENGLAND	PULMONARY SURFACTANTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED		√			Moving into tariff
PRIVIGEN	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
RIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B07/P/a; TA75, TA106, TA200	NICE	NICE	NICE AUDIT PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			√		Moving into tariff
RILONACEPT	CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Moving into tariff
SANDOGLOBULIN	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
SARILUMAB	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√		Now covered by comment 8
SECUKINUMAB	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Now covered by comment 8
SETROBUVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Never licensed
SIALIC ACID	MYOPATHY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Never licensed
SILDENAFIL	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMANORY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			√		Moving into tariff
SIRUKUMAB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√		Now covered by comment 8
SUBCUVIA	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
SUBGAM	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√		Immunoglobulin products simplified to IV or sc
SUSOCTOCOG ALFA (OBIZUR)	HAEMOPHILIA A	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Blood factor products simplified to blood factor product VIII etc
TADALAFIL	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMANORY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY			√		Moving into tariff
TOCILIZUMAB IV	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULT TA'S (TA247 and TA375)	NICE	NICE	NICE AUDIT			√		Now covered by comment 8
TOFACITINIB	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√		Now covered by comment 8

TREPROSTINIL DIETHANOLAMINE	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMANORY ARTERIAL HYPERTENSION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		Moving into tariff
TREPROSTINIL SODIUM	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMANORY ARTERIAL HYPERTENSION	NOT ROUTINELY COMMISSIONED FOR NEW PATIENTS - NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		Moving into tariff
TUROCTOCOG ALFA (NovoEight)	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES: See also SSC 1818	BCSH GUIDELINES	BCSH GUIDELINES			√		Blood factor products simplified to blood factor product VIII etc
USTEKINUMAB	PAEDIATRIC INDICATIONS (OR WHERE ADULT TA AVAILABLE)	NHS ENGLAND	DRUGS AFFECTING IMMUNE RESPONSE	AS PER TA455 AND ADULT TA's (TA180, TA340, TA456)	NICE	NICE	NICE	√	√		Now covered by comment 8
VEDOLIZUMAB	PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND MEDICINES FOR CHILDREN POLICY)	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULT TA's (TA 342, TA 352)	NICE	NICE	NICE AUDIT	√	√		Now covered by comment 8
VIGAM	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD		√		Immunoglobulin products simplified to IV or sc
VIVAGLOBIN	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD		√		Immunoglobulin products simplified to IV or sc

9. CINACALCET FOR COMPLEX PRIMARY PARATHYROIDISM IS IN TARIFF

10. PLEASE NOTE THAT MEDICINES FUNDED UNDER THE NHS ENGLAND MEDICINES FOR CHILDREN POLICY MAY HAVE ADDITIONAL CRITERIA WITH RESPECT TO ACCESS UNDER ADULT NICE OR NHS ENGLAND POLICY - THE POLICY CAN BE FOUND AT <https://www.england.nhs.uk/publication/commissioning-medicines-for-children-specialised-services/>

Now excluded for all indications

Statement added to comment 8

Lines added

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/ AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)	COMMENT
ANABASUM	SCLERODERMA	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
ANAKINRA	ADULT ONSET STILL'S DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170056P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	√	√			New NHS England Policy
ANIFROLUMAB	SLE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
ARIMOCLOMOL	NIEMANN-PICK DISEASE	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
AUTOLOGOUS SERUM EYE DROPS	DRY EYE	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
AVACOPAN	ANCA-POSITIVE VASCULITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
BARDOXOLONE METHYL	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMANORY ARTERIAL HYPERTENSION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
BEPERMINOGENE PERPLASMID	PERIPHERAL VASCULAR DISEASE	NHS ENGLAND	GENE THERAPY	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
BICTE CRAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
BRMAPITIDE	ACUTE SENSORINEURAL HEARING LOSS	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
BUOSUMAB	X LINKED HYPOPHOSPHATAEMIA	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	HST 8	NICE	NICE	NICE AUDIT	√	√			New exclusion
CABOTEGRAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
CALCIFIDIOL	INBORN ERRORS IN PRIMARY BILE ACID SYNTHESIS	NHS ENGLAND	OTHER ENDOCRINE DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
CANNABIDIOL (AS EPIDIOLEX)	DRAVET/LENNOX GESTAUT SYNDROME	NHS ENGLAND	CANNABINOIDS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
CENEGERMIN	NEUROTROPHIC KERATITIS	NHS ENGLAND	ATMP	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/ AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)	COMMENT
CLAZAKIZUMAB	ANTIBODY MEDICATED REJECTION	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
CRIZANLIZUMAB	SICKLE CELL DISEASE	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
CYCLIC PYRANOPTERIN MONOPHOSPHATE	MOLYBDENUM COFACTOR DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
DARBOPOETIN ALPHA	DIALYSIS-INDUCED ANAEMIA	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS - IRON OVERLOAD	RENAL DIALYSIS ONLY, INCLUDING VIA OUTPATIENTS, AND ONLY AS PER NICE CG114	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			√		Moved from service exclusion to full exclusion
DICHLORPHENAMIDE	PRIMARY HYPO AND HYPERKALAEMIC PERIODIC PARALYSIS	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
DIROXIMEL FUMARATE	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
DOMAGROZUMAB	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
EDASALONEXENT	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
EMAPALUMAB	HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
EMICIZUMAB	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170067/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	PRODUCTS ON CMU FRAMEWORK		√			New exclusion
EMTRICITABINE +TENOFIVIR + DARUNAVIR + COBICISTAT	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F03/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET			√		New NHS England Policy
EMTRICITABINE +TENOFIVIR + ELVITEGRAVIR + COBICISTAT	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F03/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET			√		New NHS England Policy
EPOETIN ALPHA, BETA, THETA AND ZETA	DIALYSIS-INDUCED ANAEMIA	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS - IRON OVERLOAD	RENAL DIALYSIS ONLY, INCLUDING VIA OUTPATIENTS, AND ONLY AS PER NICE CG114	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			√		Moved from service exclusion to full exclusion
ETELCALCETIDE	HYPERPARATHYROIDISM - DIALYSIS PATIENTS ONLY	NHS ENGLAND	DRUGS FOR MINERAL BONE DISORDERS	TA448	NICE	NICE		√			√	Moved from service exclusion to full exclusion
EVEROLIMUS (VOTUBIA®)	SEIZURES ASSOCIATED WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBULAR SCLEROSIS	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170093P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√			New NHS England Policy
GALUNISERTIB	CANCER	NHS ENGLAND	MYELODYSPLASTIC SYNDROME	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
GEMCITABINE (WITH CAPECITABINE)	CANCER	NHS ENGLAND	CANCER EXCLUSION	NHS ENGLAND POLICY 170101P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	SACT	√	√			New NHS England Policy
GIVOSIRAN	HEPATIC PORPHYRIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
HUMAN ALPHA-1 PROTEINASE INHIBITOR	EMPHYSEMA	NHS ENGLAND	DRUGS USED FOR EMPHYSEMA	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
IMETELSTAT	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
INEBILIZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
INOTERSEN	AMYLOIDOSIS	NHS ENGLAND	UNCLASSIFIED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
INTERFERON ALFA N3	MIDDLE EAST RESPIRATORY SYNDROME		IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
INTRAVENOUS NORMAL HUMAN IMMUNOGLOBULINS	MULTIPLE INDICATIONS	NHS ENGLAND	INTRAVENOUS NORMAL HUMAN IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD NATIONAL IMMUNOGLOBULIN DATA BASE			√		Replaces all IV branded names
LANADELUMAB	HEREDITARY ANGIOEDEMA	NHS ENGLAND	ALLERGIC EMERGENCIES	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/ AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)	COMMENT
LANTHANUM CARBONATE	ADULT RENAL DIALYSIS ONLY	NHS ENGLAND	PHOSPHATE BINDING AGENTS		TRUST GUIDELINES	TRUST GUIDELINES					√	Moved from service exclusion to full exclusion
LERONLIMAB	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
LEVOKETOCONAZOLE	CUSHING'S DISEASE	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
LUSPATERCEPT	CANCER	NHS ENGLAND	MYELODYSPLASTIC SYNDROME	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
MARALIXIBAT	ALAGILLE SYNDROME	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
MARIBAVIR	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
MARAVIROC	NATALIZUMAB INDUCED PML	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY STATEMENT 170040P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New NHS England Policy
MEXILETINE	NON DYSTROPHIC MYOTONIA	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
NUSINERSEN	SPINAL MUSCULAR ATROPHY	NHS ENGLAND	NEURODEGENERATIVE CONDITIONS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY STATEMENT 170038P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion and NHS England Policy
PARICALCITOL	HYPERPARATHYROIDISM	NHS ENGLAND	OTHER ENDOCRINE DRUGS	AS PER CINACALCIT	AS PER CINACALCIT	AS PER CINACALCIT	AS PER CINACALCIT				√	Moved from service exclusion to full exclusion
PATISIRAN	AMYLOIDOSIS	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
PEGUNIGALSIDASE ALFA	FABRY'S DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
PEGVALIASE	PHENYLKETONURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
PEMBROLIZUMAB	DRUG RESISTANT GESTATIONAL TROPHOBLASTIC NEOPLASIA	NHS ENGLAND	CANCER EXCLUSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY STATEMENT: 170027P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		√			New NHS England Policy
PIBRENTASVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA499	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	√	√			New exclusion
RAVULIZUMAB	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
RAXIBACUMAB	INHALED ANTHRAX	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
REFANALIN	PREVENTION OF DELAYED GRAFT FUNCTION	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
REPARIXIN	PREVENTION OF DELAYED GRAFT FUNCTION	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
RIMEPORIDE	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
RITUXIMAB	ANTI-NMDAR AUTOIMMUNE ENCEPHALITIS	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY:16036/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√		√		New NHS England Policy
RITUXIMAB	DERMATOMYOSITIS AND POLYMYOSITIS (ADULTS)	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY:16036/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY			√		New NHS England Policy
RITUXIMAB	MYASTHENIA GRAVIS	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY STATEMENT 170084P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√			New NHS England Policy
RIVIPANSEL SODIUM	HEPATIC VENO-OCCLUSIVE DISEASE	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
RIVIPANSEL SODIUM	SICKLE CELL DISEASE	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
RURIOCTOCOG ALFA PEGOL	HAEMOPHILIA A	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
RUZASVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
SACROSIDASE	CONGENITAL SUCRASE ISOMALTASE DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
SATRALIZUMAB	NEUROMYELITIS OPTICA	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/ AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)	COMMENT
SEVELAMER	ADULT RENAL DIALYSIS ONLY	NHS ENGLAND	PHOSPHATE BINDING AGENTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES					√	Moved from service exclusion to full exclusion
SIPONIMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
SIROLIMUS (RAPAMUNE)	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		TA481, TA482 NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	NICE	NICE	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			√*	√*	Moved from service exclusion to full exclusion
SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	MULTIPLE INDICATIONS	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD NATIONAL IMMUNOGLOBULIN DATA BASE			√		Immunoglobulin products simplified to IV or sc
SUCROFERRIC OXYHYDROXIDE	ADULT RENAL DIALYSIS ONLY	NHS ENGLAND	PHOSPHATE BINDING AGENTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES					√	Moved from service exclusion to full exclusion
TOCILIZUMAB	ADULT ONSET STILL'S DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY 170056P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√			New NHS England Policy
TRIEPTANOIN	PYRUVATE CARBOXYLASE DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
UPRIFOSBUVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
VATIQUINONE	FRIEDREICHS ATAXIA	NHS ENGLAND	NEURODEGENERATIVE CONDITIONS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
VELMANASE ALFA	ALPHA MANNOSIDASE DEFICIENCY	NHS ENGLAND	DRUGS USED TO TREAT ALPHA MANNOSIDOSIS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
VESTRONIDASE ALFA	MUCOPOLYSACCHARIDOSIS VII	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
VOLANESORSSEN	FAMILIAL CHYLOMICRONEMIA SYNDROME	NHS ENGLAND	LIPID-REGULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
VONICOG ALFA	VON WILLEBRAND DEFICIENCY	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
VORETIGENE NEPARVOVEC	LEBERS DISEASE	NHS ENGLAND	RETINAL DISORDERS/INTRAOCULAR LENS REPLACEMENT SURGERY	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
VORETIGENE NEPARVOVEC	INHERITED RETINAL DISORDERS	NHS ENGLAND	RETINAL DISORDERS/INTRAOCULAR LENS REPLACEMENT SURGERY	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
VOXELOTOR	SICKLE CELL DISEASE	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
VX-210	SPINAL CORD INJURY	NHS ENGLAND	NOVEL - NO GROUP NAME AGREED	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			New exclusion
ALECTINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 536	NICE	NICE	SACT	√		√		Added for NICE TA and not listed
ARSENIC TRIOXIDE	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 526 NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY STATEMENT 170072P	NICE	NICE	SACT	√		√		Added for NICE TA and NHS England policy and not listed
AVELUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 517 CDF	NICE CDF	NICE CDF	SACT	√		√		Added for NICE TA and not listed
AXICABTAGENE CILOLEUCEL	CANCER	CDF	ATMP	TA 559	CDF	CDF	SACT	√	√			Added for NICE TA and not listed
BRIGATINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA571	NICE	NICE	SACT	√		√		Added for NICE TA and not listed
DINUTUXIMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 538	NICE	NICE	SACT	√		√		Added for NICE TA and not listed
DOCETAXEL	CANCER	NHS ENGLAND	CANCER EXCLUSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY STATEMENT B15/PS/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	SACT	√		√		Added for NHS England policy and not listed
GEMTUZUMAB OZOGAMICIN	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 545	NICE	NICE	SACT	√	√			Added for NICE TA and not listed
INOTUZUMAB OZOGAMICIN	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 541	NICE	NICE	SACT	√	√			Added for NICE TA and not listed
LIPOSOMAL CYTARABINE-DAUNORUBICIN	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 522	NICE	NICE	SACT	√		√		Added for NICE TA and not listed

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/ AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)	COMMENT
LUTETIUM (177Lu) OXODOTREOTIDE	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 539	NICE	NICE	SACT	√	√			Added for NICE TA and not listed
MIDOSTAURIN	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 523	NICE	NICE	SACT	√		√		Added for NICE TA and not listed
NIRAPARIB	CANCER	CDF	CANCER EXCLUSION	CDF (TA 528)	CDF	CDF	SACT	√		√		Added for NICE TA and not listed
TISAGENLECLEUCEL	CANCER	CDF	ATMP	CDF (TA 554, TA567)	NICE CDF	NICE CDF	SACT	√	√			Added for NICE TA and not listed

Lines Changed

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/ AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)	COMMENT
ALEMTUZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	TA312 AND NHS ENGLAND POLICY STATEMENT 170075P	NICE	NICE	NICE AUDIT	√		√****		Updated for NHS England Policy
ANAKINRA	PERIODIC FEVERS AND AUTOINFLAMMATORY CONDITIONS	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170062P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	√	√			Updated for NHS England Policy
BENRALIZUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	NICE TA 565	NICE	NICE	NICE AUDIT	√	√			Updated for NICE TA
BORTEZOMIB	CANCER	NHS ENGLAND/ CDF	ANTINEOPLASTIC DRUGS	TA129, TA228, TA311, TA 378 CDF POLICY NOT ROUTINELY COMMISSIONED (NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170035P, 170074P)	NICE CDF	NICE CDF	SACT			√		Updated for NHS England Policy
CERLIPONASE ALFA	NEURONAL CEROID LIPOFUSCINOSIS	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY STATEMENT 170017/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Updated for NHS England Policy
CINACALCET	HYPERPARATHYROIDISM	NHS ENGLAND	DRUGS FOR MINERAL BONE DISORDERS	TA 117 NHS ENGLAND POLICY 16034/P	NICE NHS ENGLAND POLICY	NICE NHS ENGLAND POLICY					√	Updated for NHS England Policy
CRIZOTINIB	CANCER	NHS ENGLAND/ CDF	PROTEIN KINASE INHIBITORS	NICE TA 406, 422 CDF (TA 529)	NICE CDF	NICE CDF	SACT	√		√		Updated for NICE TA
DABRAFENIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA321, TA396 & TA 544	NICE	NICE	SACT	√ (not TA321)	√			Updated for NICE TA
DASATINIB	CANCER	NHS ENGLAND/ CDF	PROTEIN KINASE INHIBITORS	NICE TA 425, 426	NICE CDF	NICE CDF	SACT			√		Reference to CDF removed
GLATIRAMER	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA527 & NHS ENGLAND POLICY: D04/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER NHSE POLICY	√		√****		Updated for NICE MTA
INFLIXIMAB	PULMONARY SARCOIDOSIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 170088P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Updated for NHS England Policy
INTERFERON BETA	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA 527 NHS ENGLAND POLICY: D04/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER NHSE POLICY	√		√****		Updated for NICE MTA
LENALIDOMIDE	CANCER	NHS ENGLAND/ CDF	IMMUNOMODULATING DRUGS	TA171, TA322 CDF POLICY	NICE CDF	NICE CDF	SACT			√		Reference to CDF removed
LEVOFLOXACIN (INHALED)	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NHS ENGLAND POLICY 170078P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		√			Updated for NHS England Policy
LOMITAPIDE	HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	NHS ENGLAND	LIPID-REGULATING DRUGS	NHS ENGLAND POLICY 170059P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		√			Updated for NHS England Policy
METRELEPTIN	DYSLIPIDAEMIA	NHS ENGLAND	OTHER ENDOCRINE DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170095P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY		√			Updated for NHS England Policy
OCRELIZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	TA 533	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	√	√			Updated for NICE TA

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/ AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)	COMMENT
PEMBROLIZUMAB	CANCER INDICATIONS	NHS ENGLAND/CDF	CANCER EXCLUSION	TA 357, TA366, TA428, TA531 CDF POLICY (TA 447 (replaced by TA531), TA 519, TA522 TA540, TA553 & TA557)	NICE CDF	NICE CDF	SACT	√		√		Updated for NICE TA
REGORAFENIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA488 & TA555	NICE	NICE	SACT	√		√		Updated for NICE TA
RITUXIMAB	CONNECTIVE TISSUE DISEASE - INTERSTITIAL LUNG DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 170015/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Updated for NHS England Policy
RITUXIMAB	CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 170026/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Updated for NHS England Policy
RITUXIMAB	MEMBRANOUS NEPHROPATHY	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 16047/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Updated for NHS England Policy
RITUXIMAB	PRIMARY SJOGREN'S SYNDROME (PSS)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 16048/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Updated for NHS England Policy
SAPROPTERIN	ADULTS AND CHILDREN WITH PHENYLKETONURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED (NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170103P)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Updated for NHS England Policy
SELEXIPAG	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 170104P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		√			Updated for NHS England Policy
SORAFENIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA 474 & TA 535	NICE	NICE	SACT	√		√		Updated for NICE TA
TEMSIROLIMUS	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED (TA178)	IFR	IFR	SACT			√		Reference to CDF removed and NRC added
TERIPARATIDE	MALE AND JUVENILE OSTEOPOROSIS	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NHS ENGLAND CLINICAL COMMISSIONING POLICY STATEMENT 170064P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√			Updated for NHS England Policy
TOCILIZUMAB	GIANT CELL ARTERITIS	NHS ENGLAND	CYTOKINE MODULATORS	TA 518	NICE	NICE	NICE AUDIT	√	√			Updated for NICE TA
TOCILIZUMAB IV	JUVENILE ARTHRITIS- PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d; TA 373	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√		√		Removed reference to IV as SC now licensed for JIA
TRIENTENE	WILSONS DISEASE	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND CLINICAL COMMISSIONING POLICY 170094P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√			Updated for NHS England Policy
VANDETANIB	THYROID CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED (TA550)	IFR	IFR	SACT		√			Updated for NICE TA
ATEZOLIZUMAB	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	TA 520 & TA 525 CDF (TA 492)	NICE CDF	NICE CDF	SACT	√		√		Updated for NICE TA
AUTOLOGOUS CHONDROCYTE IMPLANTATION	ARTICULAR CARTILAGE DEFECT	NHS ENGLAND		TA 477 & TA 508	NICE	NICE	NICE AUDIT	√	√			Updated for NICE TA
BENDAMUSTINE	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	TA216 CDF POLICY NHS ENGLAND POLICY (WITH RITUXIMAB) 170055P, 17088P & 170054P	NICE CDF NHS ENGLAND POLICY	NICE CDF NHS ENGLAND POLICY	SACT	√ (Not for all policies)		√		Updated for NHS England Policy
BRENTUXIMAB	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	TA446 (replaced by TA524), TA478, TA524 CDF POLICY	NICE CDF	NICE CDF	SACT	√		√		Updated for NICE TA Reference to CDF removed
CABOZANTINIB	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	TA 463, TA516 & TA 542	NICE	NICE	SACT	√		√		Updated for NICE TA Reference to CDF removed
ERIBULIN	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	NICE TA 423 CDF POLICY	NICE CDF	NICE CDF	SACT	√		√		Blueteq requirement added
IBRUTINIB	CANCER	NHS ENGLAND/CDF	PROTEIN KINASE INHIBITORS	TA429, TA502 CDF (TA491)	NICE CDF	NICE CDF	SACT	√		√		Updated for NICE TA
LENVATINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA498, TA 535 & TA 551	NICE	NICE	SACT	√		√		Updated for NICE TA
NIVOLUMAB	CANCER	NHS ENGLAND/CDF	CANCER EXCLUSION	TA 394, 400, 417, 462, 530 CDF (TA 483, TA 484, TA 490, TA 558,)	NICE CDF	NICE CDF	SACT	√		√		Updated for NICE TA
OSIMERTINIB	CANCER	CDF	CANCER EXCLUSION	CDF (TA 416)	CDF	CDF	SACT	√		√		Blueteq requirement added
PERTUZUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	NICE TA 424, TA 509 and TA 569	NICE	NICE	SACT	√		√		Updated for NICE TA
RADIUM-223 DICHLORIDE	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	NICE TA 376, TA 412	NICE CDF	NICE CDF	SACT		√			Reference to CDF removed
TALIMOGENE LAHERPAREPVEC	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 410	NICE	NICE	SACT	√	√			Blueteq requirement added
TIVOZANIB	CANCER	CDF	CANCER EXCLUSION	TA 512	CDF	CDF	SACT	√		√		Reference to CDF removed

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/ AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)	COMMENT
TRAMETINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 396 & TA 544	NICE	NICE	SACT	√		√		Updated for NICE TA
TRIFLURIDINE-TIPRACIL	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 405	NICE	NICE	SACT	√		√		Blueteq requirement added

8. DRUGS APPROVED BY NICE FOR ADULT CONDITIONS WILL BE COMMISSIONED IN CHILDREN AT SPECIALISED PAEDIATRIC CENTRES IF THE PATIENT MEETS THE NICE CRITERIA AND THERE IS EVIDENCE TO SUGGEST THAT THE DRUG IS SAFE AND CLINICALLY APPROPRIATE TO USE IN CHILDREN AS PER THE NHS ENGLAND MEDICINES FOR CHILDREN POLICY FOUND AT <https://www.england.nhs.uk/publication/commissioning-medicines-for-children-specialised-services/> AND A BLUETEQ FORM IS AVAILABLE. THIS INCLUDES FOR DRUGS NORMALLY COMMISSIONED BY CCG'S IN ADULTS EG ADALIMUMAB, ETANERCEPT, INFILIXIMAB ETC **PLEASE NOTE THAT MEDICINES FUNDED UNDER THE NHS ENGLAND MEDICINES FOR CHILDREN POLICY MAY HAVE ADDITIONAL CRITERIA WITH RESPECT TO ACCESS**

Updated to include link to the M4C policy